Delivered-To: tjphuhs@gmail.com Received: by 2002:a5d:44c2:0:b0:439:fcfb:30e with SMTP id z2csp3142599wrr; Tue, 17 Mar 2026 11:35:48 -0700 (PDT) X-Received: by 2002:a05:6a21:9982:b0:398:bcee:451e with SMTP id adf61e73a8af0-39b99fcccf0mr262376637.46.1773772548069; Tue, 17 Mar 2026 11:35:48 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1773772548; cv=none; d=google.com; s=arc-20240605; b=HGUvVhe+lml/iBODKu4wtnGs9mPSVu2qX8s0GifI2+pR8+psaOBi2jVmyYw/tlX6uD aThyZcWvB41oSHtqjPQJYiPa/sbS8wVWG89BRJHs9QeyN6dXW18W4/WlZLKdmJYuxOOQ lkxhZ/m6YF4BNpEKrIjeHg5pNnj2Fn+MHHtqbEmqlSbk+xY1KWr5i5SUbwth8+aBYyON 7rTIyn0FKxlw0Bn1U4EeSmUNhPINGB5m4w/nWwmkPpJjQw5PkH4oUu2t79fIxJYTM4Ab ikmNSBjiNYoQZPSx7MkXM8Jt6zezIE6ytsh8LqAMPG1S+bVa7+0Mo+TLDISMzaAQU8vY tbkg== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=lkPpZhhRXKZBcKViNI7XCr0fcpSpnKzwomQ3nHL3vn4=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=hntI57OMQ7jxe8IZRqP0XfbkwZ0M0paCMthdp23tZc8WyAaRy6RzMjrHmLheg7t/dU cDy/Qqd0qoW6et+KXBIi/9d8WToWjlxc966OpNw62/oWy35mGenDs+Es+tv9fQ0nKlLy z5qWM6JABAtqrkt0NPVR1Q2JNzfRRC8wZToqJ30P6vOr3RU77CNutvIrVnn/5Zcpxkre QLtlI8VkRd+Eu2MfJpd7MSSC6cGpSHDogfW6uuIWDWBfiGdBxNuYEbXxAYCeJsN9o70Z YapLn3ba8ILxp6oCf7n6Qqegn7AOUf+zr0OXZLaHneSKvdZg0jN/wjbrTak2UiLLF2ju ZlUQ==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d1.substack.com header.s=k1 header.b=FKu1AW0k; dkim=pass header.i=@mailgun.org header.s=mg header.b=j3PzbFyn; spf=pass (google.com: domain of bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com designates 161.38.197.117 as permitted sender) smtp.mailfrom="bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from mg-197-117.substack.com (mg-197-117.substack.com. [161.38.197.117]) by mx.google.com with UTF8SMTPS id 41be03b00d2f7-c741e6bb6desi802602a12.385.2026.03.17.11.35.47 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Tue, 17 Mar 2026 11:35:48 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com designates 161.38.197.117 as permitted sender) client-ip=161.38.197.117; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d1.substack.com header.s=k1 header.b=FKu1AW0k; dkim=pass header.i=@mailgun.org header.s=mg header.b=j3PzbFyn; spf=pass (google.com: domain of bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com designates 161.38.197.117 as permitted sender) smtp.mailfrom="bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d1.substack.com; q=dns/txt; s=k1; t=1773772547; x=1773779747; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=lkPpZhhRXKZBcKViNI7XCr0fcpSpnKzwomQ3nHL3vn4=; b=FKu1AW0k3wNyjmqaxPm9znFL0TgrLFtgrzn1aEW78P+ucXh3Yc/JToGAePuTXkPYxokpoj1CemtdP/zteCQoCCQgRLS2LwL9/O7pFAG2o1canKA/r8zf6F7c3JsopNQG8M9txNbg7W8/eg1FavtSDX5dOJGULMm9aOViT8s9UQA= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1773772547; x=1773779747; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=lkPpZhhRXKZBcKViNI7XCr0fcpSpnKzwomQ3nHL3vn4=; b=j3PzbFynWd4PRDNP2fcOcu7v7nuklpbq1R95Qp0LuH3Br/8s9RvRzf8jFvyJdTF8D1sBaWtlnvT8+X9vXiz0IxHC3o4WOZv1PfTavqxYgcqqWkgrnFDGTwcyhIs2+VHIJwvCFlarMNIk7n+1apYONzlDrwqLx+2W1jCCHXjjI4g= X-Mailgun-Sid: WyIxMWU0ZSIsInRqcGh1aHNAZ21haWwuY29tIiwiMzliMDhjNiJd X-Feedback-Id: postmaster@mg-d1.substack.com:post:614a1297c57bbbe25fa40e08:mailgun Received: by 81b5f2ae12fe414830450491d7ae4f7cac71f4d160add4b69439dbaa8e59031e with HTTP id 69b99f030e9ad2a7a20289ab; Tue, 17 Mar 2026 18:35:47 GMT X-Mailgun-Sending-Ip: 161.38.197.117 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="b3917cb8b2b4740e83170649850d48a772675f20c14bf8e4a80050d824bf" Subject: Melanotan 1 vs Melanotan 2: Same Starting Point, Very Different Compounds From: Derek from Peptide Price To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260317183541.3.3856a204e24620f5@mg-d1.substack.com> Date: Tue, 17 Mar 2026 18:35:41 +0000 Feedback-Id: post-191285147:cat-post:pub-3365367:substack Sender: Derek from Peptide Price References: In-Reply-To: Reply-To: Derek from Peptide Price List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1773772547087", "is_freemail": "true", "post_audience": "everyone", "post_id": "191285147", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --b3917cb8b2b4740e83170649850d48a772675f20c14bf8e4a80050d824bf Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/melanotan-1= -vs-melanotan-2-same-starting For research and educational purposes only. Not medical advice. These two get lumped together constantly. Same name, same origin, similar p= urpose =E2=80=94 so people assume they=E2=80=99re basically the same thing = with different numbers. They=E2=80=99re not. Understanding why requires a q= uick look at what each one is actually doing at the receptor level. Where They Come From Both MT1 and MT2 were developed at the University of Arizona as synthetic a= nalogs of alpha-melanocyte stimulating hormone =E2=80=94 =CE=B1-MSH =E2=80= =94 a naturally occurring peptide your body already produces. =CE=B1-MSH pl= ays a central role in regulating pigmentation, appetite, inflammation, and = sexual function by binding to a family of receptors called melanocortin rec= eptors (MC1R through MC5R). The researchers weren=E2=80=99t trying to create a tanning peptide. They we= re trying to understand the melanocortin system =E2=80=94 and in doing so, = built two analogs that interact with it very differently. The Mechanism: Why Structure Matters MT1 is a linear peptide, meaning its amino acid chain runs straight. MT2 is= cyclic =E2=80=94 the chain loops back on itself. That=E2=80=99s not a mino= r detail. It fundamentally changes which receptors each compound binds to a= nd how strongly. Your skin contains melanocytes =E2=80=94 cells responsible for producing me= lanin, the pigment that gives skin its color. Those melanocytes express MC1= R on their surface. When =CE=B1-MSH (or a synthetic analog) binds to MC1R, = it triggers a signaling cascade that upregulates melanin production. More m= elanin means darker skin. This is the core tanning mechanism both compounds= share. Where they diverge is receptor selectivity. MT1 binds primarily to MC1R. That=E2=80=99s largely where its activity begi= ns and ends. The result is targeted melanin stimulation with minimal downst= ream effects at the other receptors. MT2 binds to MC1R as well =E2=80=94 but it also has meaningful activity at = MC3R, MC4R, and MC5R. MC4R in particular is expressed heavily in the hypoth= alamus and is involved in regulating appetite, energy balance, and sexual f= unction. This is why MT2 produces appetite suppression and sexual effects t= hat MT1 doesn=E2=80=99t. It=E2=80=99s not a bonus =E2=80=94 it=E2=80=99s a = direct consequence of its broader receptor profile. And that same breadth i= s what drives the more pronounced side effects. Think of it this way: MT1 is a targeted signal to your melanocytes. MT2 is = a louder, less specific signal that hits multiple systems at once. What That Looks Like in Practice MT1 produces a gradual, even tan. Existing freckles and moles will darken = =E2=80=94 this is expected, since those areas already have higher melanocyt= e activity. The effect builds over weeks and is dose-dependent. Outside of = that, the functional impact is minimal. MT2 produces the same tanning effect, plus appetite suppression that some r= esearch subjects find significant, plus pro-erectile and libido-related eff= ects driven by MC4R activity. You=E2=80=99re essentially getting multiple s= ystems activated from a single compound. The tradeoff is side effects. Nausea with MT2 is common, particularly durin= g the loading phase, and is tied to MC4R and MC3R activity in the gut and b= rain. Facial flushing occurs for similar reasons. MT1=E2=80=99s side effect= profile is considerably milder =E2=80=94 some nausea, occasional flushing,= but at much lower rates and severity. Safety Data This is where MT1 has a meaningful advantage. It=E2=80=99s been through for= mal clinical trials and holds regulatory approval in Europe and Australia u= nder the brand name Scenesse, used to treat erythropoietic protoporphyria = =E2=80=94 a rare disorder that causes severe light sensitivity. That approv= al doesn=E2=80=99t extend to cosmetic tanning, but it does mean MT1 has doc= umented human safety data that MT2 simply doesn=E2=80=99t have. The open question for both compounds is long-term melanocyte stimulation an= d melanoma risk. Activating MC1R repeatedly over time =E2=80=94 and by exte= nsion, continuously pushing melanocytes to produce melanin =E2=80=94 is not= something we have definitive long-term data on in healthy individuals usin= g these compounds cosmetically. MT1=E2=80=99s selectivity may theoretically= carry a lower risk profile than MT2=E2=80=99s broader activity, but that r= emains an open question, not a confirmed advantage. Both require the same baseline precautions: dermatology appointment before = starting, photo documentation of existing moles, and regular skin checks go= ing forward. Dosing MT1=E2=80=99s shorter half-life means more frequent dosing to sustain the e= ffect. MT1: Start: 0.25=E2=80=930.5mg to assess tolerance Loading: 0.5=E2=80=931mg daily for 2=E2=80=934 weeks Maintenance: 0.5=E2=80=931mg 2=E2=80=933x per week MT2: Start: 0.1=E2=80=930.25mg to assess tolerance Loading: 0.25=E2=80=930.5mg daily for 1=E2=80=933 weeks Maintenance: 0.5mg 1=E2=80=932x per week MT2 achieves a comparable tan at lower doses and less frequent intervals. T= he convenience advantage is real. Whether it outweighs the side effect prof= ile depends on what you=E2=80=99re optimizing for. How to Choose MT1 makes more sense if tanning is your only objective, if you had a rough = time tolerating MT2, or if you want the compound with more clinical data be= hind it. It costs more per dose and requires more frequent administration = =E2=80=94 those are the real tradeoffs. MT2 makes more sense if you want the broader effect profile, if dosing conv= enience matters, or if you=E2=80=99ve used it before and handle it well. It= =E2=80=99s also more cost-effective. Combining them is an option some people use to get the tanning benefit of M= T1 while running low-dose MT2 for the other effects =E2=80=94 reducing the = MT2 dose needed and keeping side effects more manageable. Most people won= =E2=80=99t need to go that route, but it=E2=80=99s a legitimate approach fo= r those who know how they respond to each. On Sun Exposure Both compounds stimulate melanin production independent of UV exposure, but= UV does accelerate and deepen the effect. The mistake is treating that as = license to spend more time in direct sun. It isn=E2=80=99t. The goal is ach= ieving color with less UV =E2=80=94 not using a peptide as cover for adding= more. Questions below. Keep it research-focused. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNVEk0TlRFME55d2lhV0YwSWpveE56Y3pOe= mN5TlRRM0xDSmxlSEFpT2pFNE1EVXpNRGcxTkRjc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LnpoVlhDNENmXzN0eEdsSWc4d1hTMEotekZ= PMEx1RTF3ejdSSmtCNUpGZHciLCJwIjoxOTEyODUxNDcsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzczNzcyNTQ3LCJleHAiOjIwODkzNDg1NDcsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.ZgCJLG6bhMDT_jpPs2usjU4twYgOwDvu1uNn1p4= Idnc? --b3917cb8b2b4740e83170649850d48a772675f20c14bf8e4a80050d824bf Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Melanotan 1 vs Melanotan= 2: Same Starting Point, Very Different Compounds3D""
For research and educational purposes only.
͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­
<= /tbody>
Forwar= ded this email? Subscribe= here for more

Melanotan 1 vs Melanotan 2: Same Starting Point, = Very Different Compounds

Derek
 
3D""
<= table role=3D"presentation" width=3D"38" border=3D"0" cellspacing=3D"0" cel= lpadding=3D"0">
3D""=
3D""
<= /td>
3D""=
READ IN APP<= img class=3D"icon text-icon" src=3D"https://substackcdn.com/image/fetch/$s_= !ET-_!,w_36,c_scale,f_png,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsu= bstack.com%2Ficon%2FLucideArrowUpRight%3Fv%3D4%26height%3D36%26fill%3Dnone%= 26stroke%3D%2523808080%26strokeWidth%3D2" width=3D"18" height=3D"18" style= =3D"min-width: 18px;min-height: 18px;border: none;vertical-align: middle;ma= rgin-right: 0;margin-left: 0;max-width: 18px" alt=3D"">
&nb= sp;

For rese= arch and educational purposes only. Not medical advice.

The= se two get lumped together constantly. Same name, same origin, similar purp= ose — so people assume they’re basically the same thing with di= fferent numbers. They’re not. Understanding why requires a quick look= at what each one is actually doing at the receptor level.

Upgr= ade to paid

Where They Come From

Both MT1 and MT2 were developed at the University o= f Arizona as synthetic analogs of alpha-melanocyte stimulating hormone R= 12; α-MSH — a naturally occurring peptide your body already prod= uces. α-MSH plays a central role in regulating pigmentation, appetite,= inflammation, and sexual function by binding to a family of receptors call= ed melanocortin receptors (MC1R through MC5R).

The research= ers weren’t trying to create a tanning peptide. They were trying to u= nderstand the melanocortin system — and in doing so, built two analog= s that interact with it very differently.

The Mechani= sm: Why Structure Matters

MT1 is a linear peptide,= meaning its amino acid chain runs straight. MT2 is cyclic — the chai= n loops back on itself. That’s not a minor detail. It fundamentally c= hanges which receptors each compound binds to and how strongly.

Your skin contains melanocytes — cells responsible for producing= melanin, the pigment that gives skin its color. Those melanocytes express = MC1R on their surface. When α-MSH (or a synthetic analog) binds to MC1= R, it triggers a signaling cascade that upregulates melanin production. Mor= e melanin means darker skin. This is the core tanning mechanism both compou= nds share.

Where they diverge is receptor selectivity.

<= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;">MT1 binds primarily to MC1R. That’s largely where its act= ivity begins and ends. The result is targeted melanin stimulation with mini= mal downstream effects at the other receptors.

MT2 binds to= MC1R as well — but it also has meaningful activity at MC3R, MC4R, an= d MC5R. MC4R in particular is expressed heavily in the hypothalamus and is = involved in regulating appetite, energy balance, and sexual function. This = is why MT2 produces appetite suppression and sexual effects that MT1 doesn&= #8217;t. It’s not a bonus — it’s a direct consequence of = its broader receptor profile. And that same breadth is what drives the more= pronounced side effects.

Think of it this way: MT1 is a ta= rgeted signal to your melanocytes. MT2 is a louder, less specific signal th= at hits multiple systems at once.

What That Looks Lik= e in Practice

MT1 produces a gradual, even tan. Ex= isting freckles and moles will darken — this is expected, since those= areas already have higher melanocyte activity. The effect builds over week= s and is dose-dependent. Outside of that, the functional impact is minimal.=

MT2 produces the same tanning effect, plus appetite suppre= ssion that some research subjects find significant, plus pro-erectile and l= ibido-related effects driven by MC4R activity. You’re essentially get= ting multiple systems activated from a single compound.

The= tradeoff is side effects. Nausea with MT2 is common, particularly during t= he loading phase, and is tied to MC4R and MC3R activity in the gut and brai= n. Facial flushing occurs for similar reasons. MT1’s side effect prof= ile is considerably milder — some nausea, occasional flushing, but at= much lower rates and severity.

Safety Data<= /p>

This is where MT1 has a meaningful advantage. It’s be= en through formal clinical trials and holds regulatory approval in Europe a= nd Australia under the brand name Scenesse, used to treat erythropoietic pr= otoporphyria — a rare disorder that causes severe light sensitivity. = That approval doesn’t extend to cosmetic tanning, but it does mean MT= 1 has documented human safety data that MT2 simply doesn’t have.

<= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;">The open question for both compounds is long-term melanocyte st= imulation and melanoma risk. Activating MC1R repeatedly over time — a= nd by extension, continuously pushing melanocytes to produce melanin —= ; is not something we have definitive long-term data on in healthy individu= als using these compounds cosmetically. MT1’s selectivity may theoret= ically carry a lower risk profile than MT2’s broader activity, but th= at remains an open question, not a confirmed advantage.

Bot= h require the same baseline precautions: dermatology appointment before sta= rting, photo documentation of existing moles, and regular skin checks going= forward.

Dosing

MT1’s= shorter half-life means more frequent dosing to sustain the effect.

MT1:

  • Start: 0.25–0.5mg to assess toleranc= e

  • Loading: 0.5= 211;1mg daily for 2–4 weeks

  • Maintenance: 0.5–1mg 2–3x per week

    • MT2:

    • Start: 0.1–0.25mg to assess tol= erance

    • Loading: 0= =2E25–0.5mg daily for 1–3=20= weeks

    • Maintenance: 0.5mg 1–2x per week

      • MT2 achieves a comparable tan at lower doses and less freque= nt intervals. The convenience advantage is real. Whether it outweighs the s= ide effect profile depends on what you’re optimizing for.

      How to Choose

      MT1 makes more sense if= tanning is your only objective, if you had a rough time tolerating MT2, or= if you want the compound with more clinical data behind it. It costs more = per dose and requires more frequent administration — those are the re= al tradeoffs.

      MT2 makes more sense if you want the broader = effect profile, if dosing convenience matters, or if you’ve used it b= efore and handle it well. It’s also more cost-effective.

      Combining them is an option some people use to get the tanning benefit= of MT1 while running low-dose MT2 for the other effects — reducing t= he MT2 dose needed and keeping side effects more manageable. Most people wo= n’t need to go that route, but it’s a legitimate approach for t= hose who know how they respond to each.

      On Sun Exposu= re

      Both compounds stimulate melanin production ind= ependent of UV exposure, but UV does accelerate and deepen the effect. The = mistake is treating that as license to spend more time in direct sun. It is= n’t. The goal is achieving color with less UV — not using a pep= tide as cover for adding more.

      Questions below. Keep it resea= rch-focused.

      Upgrad= e to paid

Y= ou're currently a free subscriber to Peptide Price. For the full experience, Upgrade to paid

 
=
3D"=Share=
 
 
3D""Like
3D""Comment
3D""Restack
 

© 2026 Derek Pruski
548 Marke= t Street PMB 72296, San Francisco, CA 94104
Unsubscribe

3D"Start

<= /td>3D""3D"" --b3917cb8b2b4740e83170649850d48a772675f20c14bf8e4a80050d824bf--